Two-year follow-up of a thyroid cartilage metastasis from prostate cancer: A case report
| dc.contributor.author | Kobeissi, Jana M. | |
| dc.contributor.author | Youssef, Bassem Y. | |
| dc.contributor.author | Mobayed, Tala | |
| dc.contributor.department | Radiation Oncology | |
| dc.contributor.faculty | Faculty of Medicine (FM) | |
| dc.contributor.institution | American University of Beirut | |
| dc.date.accessioned | 2025-01-24T12:12:27Z | |
| dc.date.available | 2025-01-24T12:12:27Z | |
| dc.date.issued | 2023 | |
| dc.description.abstract | Few case reports describe metastatic prostate cancer to the thyroid cartilage. While earlier reports identified the metastatic lesions upon developing symptoms, more recent ones have detected them via prostate-specific membrane antigen positron emission tomography (PSMA PET). Herein, we report the case of a patient with metastatic castrate-resistant prostate cancer and a PSMA PET-detected lesion in the thyroid cartilage. Over the course of 2 years, he received multiple lines of chemotherapy and hormonal therapy, and his overall disease status fluctuated — some nodal and bony metastases resolved while others appeared anew. His thyroid cartilage lesion, however, slowly progressed in a consistent fashion with increasing uptake on successive PSMA PET images. Apart from mild dysphonia, the patient remained to be asymptomatic from this lesion, and no local therapies were used. To our knowledge, this is the first close follow-up of prostate cancer metastatic to the thyroid cartilage, shedding light on the course of such lesions and helping answer management-related questions, which are particularly relevant as more occult metastases are discovered in the PSMA PET era. © 2023 | |
| dc.identifier.doi | https://doi.org/10.1016/j.radcr.2023.07.071 | |
| dc.identifier.eid | 2-s2.0-85168369343 | |
| dc.identifier.uri | http://hdl.handle.net/10938/32778 | |
| dc.language.iso | en | |
| dc.publisher | Elsevier Inc. | |
| dc.relation.ispartof | Radiology Case Reports | |
| dc.source | Scopus | |
| dc.subject | Laryngeal metastases | |
| dc.subject | Occult metastases | |
| dc.subject | Prostate adenocarcinoma | |
| dc.subject | Psma pet | |
| dc.subject | Cabazitaxel | |
| dc.subject | Docetaxel | |
| dc.subject | Enzalutamide | |
| dc.subject | Fluorodeoxyglucose | |
| dc.subject | Prostate specific membrane antigen | |
| dc.subject | Testosterone | |
| dc.subject | Tracer | |
| dc.subject | Adult | |
| dc.subject | Androgen deprivation therapy | |
| dc.subject | Article | |
| dc.subject | Asymptomatic disease | |
| dc.subject | Body weight loss | |
| dc.subject | Bone metastasis | |
| dc.subject | Cancer chemotherapy | |
| dc.subject | Cancer hormone therapy | |
| dc.subject | Cancer patient | |
| dc.subject | Case report | |
| dc.subject | Clinical article | |
| dc.subject | Disease duration | |
| dc.subject | Disease exacerbation | |
| dc.subject | Dysphonia | |
| dc.subject | Follow up | |
| dc.subject | Gleason score | |
| dc.subject | Human | |
| dc.subject | Lymph node metastasis | |
| dc.subject | Male | |
| dc.subject | Metastatic castration resistant prostate cancer | |
| dc.subject | Middle aged | |
| dc.subject | Multiple cycle treatment | |
| dc.subject | Oncology | |
| dc.subject | Palliative therapy | |
| dc.subject | Positron emission tomography-computed tomography | |
| dc.subject | Radiation oncology | |
| dc.subject | Thyroid cartilage | |
| dc.subject | Thyroid metastasis | |
| dc.title | Two-year follow-up of a thyroid cartilage metastasis from prostate cancer: A case report | |
| dc.type | Article |
Files
Original bundle
1 - 1 of 1